Koong Laboratory

The Koong Lab is supported by an experienced research team. We have previously shown that the IRE1alpha-XBP1 pathway, a key component of the unfolded protein response (UPR), was activated by hypoxia and endoplasmic reticulum (ER) stress. Since identifying IRE1alpha-XBP1 as a potential therapeutic target in cancer, our laboratory has completed a high throughput small molecule screen of >120,000 compounds for inhibitors of this pathway.

We identified a class of compounds that selectively inhibit IRE1alpha and demonstrate potent anti-cancer activity. We developed several computational biology methods of analyzing the drug screening data to improve the efficiency of drug discovery. We also completed a genome-wide siRNA screen to identify other genes that are required for the activation of IRE1alpha. Studies investigating the mechanisms of IRE1alpha activation will lead to the development of novel cancer therapeutics targeting this pathway.

Recently, we also identified a novel regulatory function of IRE1alpha in cellular sensitivity to ferroptosis, an iron-dependent form of non-apoptotic cell death, suggesting that targeting this pathway pharmacologically may be a novel therapeutic approach for alleviating tissue damages due to excessive ferroptosis, as well as for improving cancer therapy. 

Dr. Koong's clinical interest is in the treatment of gastrointestinal malignancies, particularly pancreatic cancer. He has pioneered the use of stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) for pancreatic cancer. The translational focus of the Koong Laboratory is to identify cancer biomarkers that facilitate clinical decision making.

Principal Investigator

Albert C. Koong, M.D., Ph.D., FACR, FASTRO
Professor and Division Head, Division of Radiation Oncology
Chair, Department of Radiation Oncology
Olga Keith and Harry Carothers Wiess Distinguished University Chair in Cancer Research

Office: 713-563-2300

@ACKoongMDPhD